Kestra Medical Technologies Ltd. ( (KMTS) ) has released its Q1 earnings. Here is a breakdown of the information Kestra Medical Technologies Ltd. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kestra Medical Technologies, Ltd. is a commercial-stage company specializing in wearable medical devices and digital healthcare solutions aimed at improving cardiovascular disease outcomes through innovative monitoring and therapeutic technologies.
In its first quarter fiscal 2026 report, Kestra Medical Technologies announced a significant revenue increase, marking a strong start to the fiscal year. The company reported a 52% rise in revenue compared to the previous year, driven by strategic advancements and market expansion.
Key financial highlights include a revenue of $19.4 million and a gross margin expansion to 45.7%, up from 32.9% the previous year. The company also saw a 51% increase in prescriptions for its ASSURE system. Despite these gains, Kestra reported a GAAP net loss of $25.8 million, attributed to increased operating expenses and non-recurring costs associated with becoming a public company.
Looking ahead, Kestra has raised its fiscal year 2026 revenue guidance to $88 million, indicating confidence in continued growth and market share capture. The company remains focused on expanding its commercial organization and enhancing revenue cycle management to support its strategic objectives.
Kestra’s management is optimistic about the future, emphasizing their commitment to achieving category leadership in the wearable defibrillator market while maintaining a focus on patient care and prescriber engagement.